Switching to an alternative ALK-inhibitor after alectinib-induced pneumonitis resulted in resolution of this adverse event

This report adds to the available literature and demonstrates that utilizing an alternative ALK-inhibitor may be a potential management strategy for drug-induced ILD/pneumonitis that allows patients to continue to receive these effective therapies. READ ARTICLE

Current Problems in Cancer: Case Reports DOI: 10.1016/j.cpccr.2020.100023

Authors: Evan Bryson, Suresh Ramalingam, Tyler Beardslee

Case StudyKirk SmithDecember 1, 2020Interstitial lung disease, Pneumonitis, Drug-induced pneumonitis, ALK-inhibitor induced pneumonitis